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Abstract At the end of 2011, about half of the 34.0 million
[31.4–35.9 million] people living with HIV infection knew
their HIV status. With large regional variations, an estimated
0.8 % of all adults aged 15 to 49 years have HIV infection
and HIV subtype diversity is increasing. Although HIV
incidence has declined in 39 countries, it is stable or increasing
in others. HIV prevalence continues to rise as antiretroviral
treatment scale-up results in fewer HIV-related deaths while
new infections continue to occur. Increased treatment uptake
is likely reducing HIV transmission in countries with large
mortality declines. Key populations, including sex workers,
men who have sex with men, transgender people, people who
inject drugs and young women in high prevalence settings
require effective prevention programs urgently. Correcting
mismatches in resource allocation and reducing community
viral load will accelerate incidence declines and affect future
epidemic trends, if concerted action is taken now.
Keywords HIV . AIDS . HIV prevalence . HIV incidence .
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Introduction
More than 30 years have passed since the first cases of what
would subsequently be known as acquired immunodeficien-
cy syndrome (AIDS) were diagnosed in New York City and
California [1]. On the scientific front, tremendous progress
has been made in identifying a retrovirus, the human immu-
nodeficiency virus (HIV), as the cause of AIDS [2••], de-
vising diagnostic tests [3] and developing effective
antiretroviral treatment (ART) regimens [4]. On the public
health front, HIV prevention approaches based on aware-
ness raising about the need for behavior change, offers of
HIV testing and counselling, and promotion of correct and
consistent male and female condom use have led to declines
in HIV incidence in many countries. New biomedical HIV
prevention modalities, such as voluntary medical male cir-
cumcision (VMMC) [5], oral pre-exposure prophylaxis (oral
PrEP) [6], topical PrEP (microbicides) [7], and early ART
for prevention [8••] purposes are showing promise. At the
same time, there is increasing recognition that the structural
determinants of HIV risk undermine people’s capacity to
avoid HIV exposure and acquisition and, if they already
have HIV infection, to prevent onward transmission.
On the one hand, there is much to celebrate. The numbers
of new cases of HIV infection in both adults and children are
falling, fewer people living with HIV are dying from AIDS-
related causes, and enabling policy frameworks have been
implemented to structure and speed progress against the
HIV epidemic. On the other hand, the size and nature of
the challenges before us underscore the fact that, despite
persistent and intensifying scientific efforts to find a cure
[9•] and to create an efficacious vaccine [10], the HIV
epidemic will be with us for decades to come. In summa-
rizing the current state of the HIV epidemic, this article will
permit readers to determine for themselves whether the glass
is optimistically ‘half-full’ or soberly ‘half-empty’.
Global Figures and Epidemic Trends
Across the globe at the end of 2011, 34.0 million [range of
uncertainty: 31.4–35.9 million] people were living with HIV
infection [11], of whom about 50 % know their HIV status
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[12]. Globally, 0.8 % of all adults aged 15 to 49 years have
HIV infection. The global figures mask large regional dif-
ferences, with sub-Saharan Africa (SSA) continuing to
shoulder the largest burden, with 69 % of all prevalent
HIV infections and close to 1 in 20 adults (4.9 %) living
with HIV. One-third of all people with HIV globally reside
in 9 countries in southern Africa that account for 2 % of the
world’s population [13]. In terms of numbers of infections,
the next most affected region is South and South-East Asia
and, when East Asia is added, the overall Asia region is
home to almost 5 million people living with HIV. Three
other regions follow, each with 1.4 million people living
with HIV: Eastern Europe and Central Asia, North America,
and Latin America. The remaining 4 regions are home to
1.49 million people in total, completing the ten-region pic-
ture of prevalent HIV infections. The ranges around the
UNAIDS estimates (Table 1) define the boundaries within
which the actual numbers lie, based on the best available
information. They remain relatively wide, reflecting the
incomplete picture that current data provide.
Every single one of the 10 regions has experienced an
increase in HIV prevalence, comparing 2011 with 2001, with
the exception of the Caribbean region that had an apparent
decline in its point estimate from 240,000 in 2001 to 230,000
in 2011. For South and South East Asia, Latin America, the
Caribbean, and North America the 2011-point estimates lie
within the 2001 ranges of uncertainty, suggesting that ob-
served increases might not be significant. However, for the
other 6 regions, sub-Saharan Africa, Eastern Europe and
Central Asia, Western and Central Europe, East Asia, the
Middle East, North Africa, and Oceania, the 2011-point esti-
mate is clearly outside the 2001 range, signalling a likely
significant increase in the numbers of people living with HIV.
HIV prevalence can rise if people are living longer with
HIV as a result of life-prolonging antiretroviral therapy or if
increasing numbers of people are newly acquiring HIV
infection. Steadily increasing access to antiretroviral therapy
is estimated to have added 14 million life-years in low- and
middle-income countries (LMIC) since 1995, with 8 million
people on ART at the end of 2011, a 20-fold increase since
2003 [11]. The result has been that from the mid-2000s the
number of people dying of AIDS-related causes has fallen
steadily. This is reflected in global tuberculosis-related AIDS
deaths declining 9 % from 2005 to 2009 and 13 % from
2009 to 2011 [14]. However, age-standardised death rates in
the two decades between 1990 and 2010 paint a different
picture: the decline of 21.5 % in all cause death rates con-
trasts starkly to the 258 % increase in the age-standardised
death rate for AIDS [15]. Similarly, years lived with disabil-
ity per 100,000 globally increased only 2.5 % for all causes
versus 109.4 % for HIV between 1990 and 2010 [16].
While absolute numbers of deaths due to HIV have been
declining, HIV incidence, ie, new HIV infections, has also
declined, falling from 3.2 million (2.9–3.4 million) in 2001
to 2.5 million (2.2–2.8 million) in 2011, despite an
expanding world population. Two-thirds of the new HIV
infections averted in 2010 and 2011 were those that would
have occurred among infants. In fact, new infections in
children over these 2 years decreased by 24 % [12]. This is
primarily due to increasing program coverage for the preven-
tion of mother-to-child transmission (PMTCT). This decline
is set to accelerate now as the Global Plan toward elimination
of new infections in children by 2015 gathers speed [17].
The overall incidence decline, which began from a peak
in 1997, partially counterbalances increasing HIV preva-
lence due to ART expansion (Fig. 1). Each person with
HIV infection will eventually require ART. An estimated
6.8 million people who are currently eligible for ART do not
have access to it [11]. The 2015 goal of 15 million people on
ART, known as ‘15 by 15’, means that these people who are
already eligible, as well as others who will become eligible
for treatment, need to be reached with treatment services by
Table 1 HIV prevalence by





Sub-Saharan Africa 23.5 million 22.1–24.8 million 4.9 4.6–5.1
South and South-East Asia 4.0 million 3.1–4.6 million 0.3 0.2–0.3
East Asia 830,000 590,000–1.2 million 0.1 <0.1–0.1
Eastern Europe and Central Asia 1.4 million 1.1–1.7 million 0.4 0.3–0.5
North America 1.4 million 1.1–1.8 million 1.0 0.6–1.0
Latin America 1.4 million 1.1–2.0 million 0.6 0.5–1.0
West and Central Europe 900,000 830,000–1.0 million 0.2 0.2–0.3
Middle, East, and North Africa 300,000 250,000–360,000 0.2 0.1–0.2
Caribbean 230,000 200,000–250,000 1.0 0.9–1.1
Oceania 53,000 47,000–60,000 0.3 0.2–0.3
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2015. The 2010 World Health Organization ART guidelines
recommend treatment initiation when CD4 cell counts fall to
350 cells/uL [4], however, in high-income countries, in-
creasingly people are starting ART at 500 cells/uL as the
benefits of earlier treatment become evident. The definitive
answer about individual clinical benefits of early treatment
is expected from the START (Strategic Timing of
Antiretroviral Therapy) trial underway in 35 countries that
will soon complete enrolment of 4000 people with CD4
counts above 500 cells/uL [18]. Participants are being ran-
domized to start treatment immediately or wait until
reaching CD4 350 cells, with follow-up planned out to
December 2015. Pending the START trial results, there is
increasing interest in a ‘test and treat’ approach [19], in
which people, particularly those more likely to be lost to
follow-up after an HIV diagnosis, may be offered ART at
the time of HIV diagnosis regardless of CD4 count.
Thus, growing numbers of people worldwide will be placed
on life-saving ART in the coming years, whether treatment
eligibility remains at CD4 350 or it increases to 500, as guide-
lines and practices change. The result will be increasing lon-
gevity for people living with HIVand continued growth in the
size of the global epidemic, despite the progress being made to
stop the constant incoming flow of new HIV infections.
As the number of people living with HIV continues to
expand, HIV subtype diversity will likely increase as HIV
continues to evolve through mutation and recombination.
Although the global HIV epidemic arose from a handful of
HIV group M viruses [20] that jumped species in the Congo
River basin likely around 1908, the HIV epidemic today is
very diverse [21••]. Advances in genomic sequencing
methods, such as deep DNA sequencing, have greatly im-
proved our understanding and analysis of HIV genetic di-
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Fig. 1 Global HIV trends,
1990–2011. Global Report [11]
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is now categorized into groups M (main), N (non-M, non-O),
O (outlier), and a tentative new group P. Group M has 9
subtypes or clades (A-D, F-H, J, and K), 51 circulating re-
combinant forms (CRF), and a large number of unique recom-
binant forms (URFs) [22]. Recombinant forms are created in
the presence of simultaneous or sequential infection with 2 or
more different HIV-1 subtypes through strand transfer during
reverse transcription [23]. Phylodynamic approaches are in-
creasingly being used to obtain estimates of sequence evolu-
tion rates and epidemic network parameters [24], with
mathematical modelling demonstrating that inter-subtype re-
combination has clearly been a substantial force in generating
HIV-1 groupM diversity [25]. Some regions, such as southern
Africa, have low viral diversity, whereas others have several
subtypes and circulating recombinants. Subtype C accounts
for 48 % of infections while subtypes A and B account for
12 % and 11 % of global HIV infections respectively [26].
Subtype specificity may be important for vaccine develop-
ment but does subtype matter for HIV progression and trans-
mission? Certain subtypes are now known to be associated
with faster HIV disease progression. Subtype D is associated
with higher viral load set points [27] and has a higher fre-
quency of syncytium formation and CXCR4 receptor use
associated with more rapid decreases in CD4 cell count.
Similar rapid CD4 declines are seen in infection with multiple
subtypes compared with infection with a single subtype [28,
29]. This underscores the importance of the positive dignity,
health, and prevention strategy in reducing the risk of super-
infection [30]. Subtype C strains use CCR5 receptors and
rarely switch to using CXCR4 or both, a switch that is nor-
mally associated with more rapid disease progression. This
may explain the slower progression seen in people with
subtype C compared with subtype D or A [31]. As for whether
certain subtypes are more easily transmitted, a study in
Uganda found that subtype A was more readily transmitted
heterosexually than subtype D [32]. Individuals who have
high viral set points and those who maintain high viral loads
in the absence of ART are more likely to transmit HIV infec-
tion [33], suggesting that they would be priority candidates for
early ART. Given the increasing recognition of the powerful
prevention benefits of ART through substantially reduced
transmission when viral load is suppressed [8••], ART scale-
up will have important effects in decreasing HIV incidence
globally at the same time that it will increase HIV prevalence.
National Responses and Trends
Some countries have made striking progress in preventing
new HIV infections while others lag behind and a few even
have increasing HIV incidence. For example, among 18 sub-
Saharan African countries with an HIV prevalence of 3 % or
more in 2011, Swaziland, South Africa, and Mozambique
had increasing HIV prevalence over the previous decade but
significantly declining HIV incidence (Table 2) while
Uganda experienced an increase in HIV prevalence along
with a 22 % increase in HIV incidence (Table 3).
In 2012, 186 countries, representing 96% of United Nations
member states, submitted comprehensive reports on their na-
tional AIDS responses to UNAIDS. These reports highlight
how well a country is performing in meeting the 2015 targets
that all countries agreed to when they signed on to the 2011
United Nations Political Declaration on HIV and AIDS:
Intensifying our efforts to eliminate HIV and AIDS [34] The
combination of these national AIDS response reports, which
include ART and prevention program coverage, with country-
specific estimates for HIV prevalence, AIDS-related mortality,
and HIV incidence, help paint a picture of what responses in
which countries are the most effective in addressing HIV.
Recent epidemic trends are analyzed by UNAIDS using pub-
lished peer-reviewed articles or through the use of recommended
modelling tools for national HIVestimations [35].
HIV incidence in adults 15–49 years old fell by more than
50 % in the decade from 2001 to 2011 in 25 countries, 12 of
which are in sub-Saharan Africa, 6 in the Caribbean, 6 in Asia,
and 1 in the Middle East. The sharpest regional declines were
in the Caribbean (42 %) and sub-Saharan Africa (25 %) [11].
Over the same period, adult HIV incidence increased by more
than 25% in 9 countries, 4 of which are in Eastern Europe and
Central Asia (Georgia, Kazakhstan, Kyrgyzstan, and the
Republic of Moldova), 4 are in Asia (Bangladesh, Indonesia,
Philippines, and Sri Lanka), and only 1 is in Africa (Guinea
Bissau). Of note, the numbers of new HIV infections had been
relatively stable in Eastern Europe and Central Asia until the
late 2000s when the increase began.
Is ART scale-up playing a role in country HIV incidence
declines? A clinical trial among discordant couples in 9 coun-
tries found a 96 % reduction in the risk of genetically-linked
HIV transmission when early ART at CD4 counts above 350
supressed viral load in the HIV-infected partner [8••]. In the
absence of treatment, infectivity is estimated to be 9 times
higher in early HIV infection and 7 times higher in late HIV
infection [36]. Further, the utility of mathematical modelling
to examine the potential impact of ARTon HIV incidence has
been explored, with a study of 12 models [37] finding broad
agreement regarding the short-term epidemiologic impact of
ambitious treatment scale-up, but more variation in longer
term projections and in the efficiency with which treatment
can reduce new infections [38].
An examination of trends in mortality could allow an as-
sessment of the possible role of ART scale-up in contributing
to declining HIV incidence. In fact, of the 14 countries that
have experienced a 50 % decline in mortality between 2005
and 2011, 7 of them had achieved 80 % or more coverage of
ART for eligible people and 3 had achieved 60 %–79 %
coverage. Nine of the 14 countries with these large mortality
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declines had a greater than 50 % decline in incidence from
2001–2011 [11]. This suggests that ART scale-up is likely
influencing HIV transmission; however the extent remains to
be determined.
What about the contribution of HIV prevention program-
ming to declining HIV incidence? UN member states have
pledged to meet Universal Access Targets [39] and
Millennium Development Goals [40] and have committed,
Table 2 African countries with HIV prevalence greater than 10 % in 2011
Countries 2001 2011 2001-2011
Prevalence Incidence Prevalence Incidence % Change inIncidence
Swaziland 22.2 4.11 26.0 2.60 - 37%
Botswana 27.0 3.48 23.4 1.00 - 71%
Lesotho 23.4 2.67 23.3 2.47 - 7%
South Africa 15.9 2.42 17.3 1.43 - 41%
Zimbabwe 25.0 2.11 14.9 1.05 - 50%
Zambia 14.4 1.89 12.5 0.80 - 58%
Namibia 15.5 2.39 13.4 0.77 - 68%
Mozambique 9.7 1.63 11.3 1.13 - 31%
Malawi 13.8 1.74 10.0 0.49 - 72%
Source: UNAIDS Report on the Global AIDS Epidemic – 2012. Accessible at: http://www.unaids.org/en/media/unaids/contentassets/documents/
epidemiology/2012/gr2012/JC2417_GR%202012_Annexes_en.pdf and http://www.unaids.org/en/dataanalysis/knowyourepidemic/
epidemiologicalfactsheets/
Note: Green shading indicates significant decrease in incidence or prevalence; yellow shading indicates moderate decrease in incidence or
prevalence; red shading indicates increase in incidence or prevalence
Table 3 African countries with HIV prevalence between 3 % and 10 % in 2011
Countries 2001 2011 2001-2011
Prevalence Incidence Prevalence Incidence % Change inIncidence
Cote d’Ivoire 6.2 0.39 3.0 0.15a  
Uganda 6.9  0.69 7.2  0.84 +22%
-54%
Tanzania 7.2  0.62 5.8  0.59 - 5%
Kenya 8.5  0.66 6.2  0.45 - 32%
CAR 8.1  0.67 4.6  0.29 - 57%
Cameroon 5.1  0.63 4.6  0.36 - 43%
Chad 3.7 nd 3.1 0.28 nd 
Congo 3.8 0.35 3.3 0.31 - 11%
Nigeria 3.7 0.42 3.7 0.36 - 14%
Source: UNAIDS Report on the Global AIDS Epidemic – 2012. Accessible at: http://www.unaids.org/en/media/unaids/contentassets/documents/
epidemiology/2012/gr2012/JC2417_GR%202012_Annexes_en.pdf and http://www.unaids.org/en/dataanalysis/knowyourepidemic/
epidemiologicalfactsheets/
Note: Green shading indicates significant decrease in incidence or prevalence; yellow shading indicates moderate decrease in incidence or
prevalence; red shading indicates increase in incidence or prevalence
a 2009 data
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for example, to 50 % reductions in sexual transmission and
50 % reductions in injecting drug use-related transmission
by 2015. To accomplish this, and other prevention goals
such as the elimination of new HIV infections in children,
countries are strengthening their combination prevention
programs. Combination prevention combines behavioral,
biomedical, and structural interventions to address both the
immediate risks and underlying causes of vulnerability to
HIV infection, as well as the pathways that link them [41]. It
is evidence-informed, human-rights based, and context-
specific. In order to be effective, prevention programs must
be tailored to local epidemics, with relevant components
delivered at an intensity, quality, and scale necessary to
achieve intended effects. Some countries have used the
‘Know Your Epidemic, Know Your Response’ process to
discover the extent of disconnects between the dynamics of
their epidemic and the resources they have committed to
addressing it [42]. Although this process can lead to re-
alignment of resources for improved cost-effectiveness, a
recent analysis of HIV prevention spending in 69 low- and
middle-income countries with a variety of epidemic types
revealed that spending patterns did not consistently reflect
either current evidence or the HIV-specific context of each
country [43•]. Recognition of the culture-specific aspects of
microepidemics in a country is an important first step toward
development of community-based organizations that can fos-
ter locally effective HIV responses [44]. In fact, bold and
collaborative leadership in local scale-up of HIV prevention
and treatment has been shown to underpin success in countries
as varied as Brazil, Botswana, Nigeria, and India [45].
With respect to sexual transmission of HIV, effective HIV
prevention programs can contribute to declining incidence
trends when they foster changes in sexual behavior toward
healthier patterns. Such prevention programming focuses on
increasing knowledge, raising awareness, building skills,
and creating safer sexual social norms. The agreed indica-
tors being tracked are sex before age 15 years, as reported
by young people age 15 to 24 years, and multiple partners in
the previous 12 months and condom use at last high-risk
sex, as reported by those aged 15–49 years. In 11 countries
with adult HIV prevalence greater than 1 %, 5 of which
experienced a greater than 50 % decline in HIV incidence,
significantly fewer young women are reporting sex before
age 15 years [11], suggesting that delayed sexual debut may
be contributing to reduced HIV incidence. Changes in the
indicators for adult sexual behavior are most striking in 3
countries with 50 % declines (Zambia, Malawi, and
Namibia), 2 countries with 26 %–49 % decreases (Kenya
and Mozambique), and 1 country with stable incidence but a
very large population (Nigeria). However, risky sex is on the
increase in some countries (Cote d’Ivoire, Guyana, and
Rwanda) and comprehensive and correct knowledge about
HIVand its transmission is suboptimal in many countries that
have an adult HIV prevalence over 1 %. For example, less
than 50% of young women in 26 of 31 countries and less than
50 % of young men in 21 of 25 countries conducting surveys
had adequate HIV-related knowledge [11].
Progress on increasing access to voluntary medical male
circumcision (VMMC) has been slow but steady since
WHO/UNAIDS recommended the procedure to reduce the
risk of sexual HIV acquisition in young men living in
countries with higher HIV prevalence [5]. The potential
impact is impressive, with mathematical modelling estimat-
ing 16.5 billion USD in cost savings by 2025 in averted HIV
infections for a 1.5 billion USD investment to reach 80 %
circumcision prevalence by 2015 in the countries with the
heaviest HIV burdens [46]. Kenya, Ethiopia, and Swaziland
have made the most progress, attaining 20 % of their national
targets. In Ethiopia and Swaziland infant male circumcision is
now offered to parents routinely. But the promise of male
circumcision will not be realized without task shifting and
the use of timesaving devices that are currently under evalu-
ation for safety and acceptability [47–49].
Key Populations
Key populations are defined as those that are key to the
dynamics of an epidemic and key to the response to it.
Without the explicit and active engagement of a key population
in the design, implementation, and evaluation of an HIV
prevention program addressing it, the program is likely to fail.
Which populations are key will be context-specific but vulner-
ability, marginalization, and inability to influence the environ-
ment within which risk is experienced are hallmarks. Legal and
policy barriers in many countries impede HIV prevention
programming for sex workers, men who have sex with men,
transgendered people, and people who inject drugs. Cultural
and economic impediments to education, self-actualization,
and financial independence combined with sexual violence
heighten HIV risk for young women in southern Africa [50].
Female sex workers were estimated in a systematic review
of studies representing almost 100,000 sex workers in 50
countries to have an overall prevalence of 11.8 % and a pooled
odds ratio of 13.5 for HIV infection. In 26 countries with
medium- and high-background HIV prevalence, HIV preva-
lence among sex workers rose to 30.7 % with an odds ratio of
11.6 [51•]. Almost 75 % of the 59 countries reporting to
UNAIDS about sex work indicated that they had implemented
comprehensive prevention programs for sex workers, howev-
er, most of these appear to be in urban settings and only 11
countries are reaching at least 80 % of sex workers in cities
[11]. Where services are provided, 85 countries report that
nearly 9 in 10 sex workers used a condom the last time they
had sex [12]. Given the disproportionate HIV burden borne by
sex workers and the likelihood of onward HIV transmission,
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this population should be prioritized for increased access to
ARTand to antiretroviral-based PrEP. However, this has to go
hand in hand with anti-stigma, anti-discrimination, and anti-
violence programs, as well as legal and policy changes and
engagement/empowerment strategies to change the risk envi-
ronment in which sex work is occurring [52].
Men who have sex with men (MSM) have a dispropor-
tionately high HIV burden, as a result of the high per-act and
per-partner transmission probabilities during anal sex, and
have higher rates of dual-variant and multiple-variant HIV
infection than heterosexual people in the same settings [53].
The global prevalence of HIV among MSM appears to have
increased from 2010 to 2012, although data are limited and
not readily comparable [11]. Although 146 countries now
include MSM in their national strategies, only 104 reported
HIV prevalence data in 2012, 62 reported prevention pro-
gram coverage among MSM, 100 reported HIV testing
coverage, and 96 reported on condom use. Median preven-
tion coverage in capital cities was 55 %, a median of 38 %
of MSM received an HIV test in the previous 12 months,
and 75 % of MSM in only 13 countries reported condom use
at last sex [11]. Although funding for HIV prevention
among MSM increased between 2006 and 2011, 92 % of
all spending on HIV programs for MSM came from inter-
national sources [11]. With a high force of infection and
clustering of HIV in MSM networks, antiretroviral-based
prevention strategies, whether PrEP for HIV-negative men
or ART for HIV-positive men, would help control epidemic
expansion but would require culturally competent care ac-
companied by decriminalization and reduction of stigma
and discrimination [54••].
Transgender women, estimated at 15 million globally, are
at extremely high risk of HIVacquisition compared with other
adults, with HIV prevalence as high as 68 % [55] and an odds
ratio of being infected of 48.8 (95 % confidence interval 12.2–
76.3) without significant differences between high-income
and low- and middle-income settings in a recent systematic
review and meta-analysis [56•]. Transgender women have a
female gender identity but a birth-assigned male sex. Lacking
access to information, services, and economic opportunities,
up to 44 % of transgender women in high-income countries
rely on sex work as their only source of income [57]. A
systematic review of studies in 14 countries on 5 continents
found that transgender women engaged in sex work are more
than 4 times as likely as other female sex workers to be living
with HIV [58]. This marginalized highly vulnerable popula-
tion is below the radar of the majority of national HIV pre-
vention programs, with the result that data on HIV prevalence
and program coverage are scarce. Only 43 % of countries
report that their national strategies address transgender people
and 40 % indicate that government service provision accounts
for less than 25 % of the programs and services that are
provided [11]. Engaging and empowering transgender women
to have a stronger voice is the only pathway to better surveil-
lance data, representation in HIV prevention research in ade-
quate numbers for analysis, effective prevention programs,
and promotion and protection of the rights of this neglected
key population.
A striking HIV prevalence, 22 times higher than that of
the general population, is found in 49 countries among
people who inject drugs (PWID), with 11 countries having
50-fold or more differences [11]. A recent systematic review
of studies from 14 countries found a significantly higher HIV
prevalence among female compared with male injectors [59],
reflecting the increased risks faced by women who inject and
who are not reached with HIV prevention services [60].
Although contaminated injecting equipment is the immediate
source, augmented by unprotected sexual intercourse, puni-
tive approaches rooted in perceptions of drug injecting as
illegal behavior are fuelling expanding epidemics, particularly
in Eastern Europe and Central Asia. Globally few countries
remain untouched. A systematic review conducted in 2007
found documented injecting drug use in 148 countries, HIV
infection associated with injecting in 120 of those countries,
and an estimated total of 15.9 million [11.0–21.2 million]
PWID, with the largest numbers being in China, the USA,
and Russia [61]. Worldwide 3 million (0.8–6 million) PWID
may be living with HIV. The HIV prevention evidence base
for injecting-related HIV is strong but many countries are
neither tracking HIV incidence nor implementing proven ef-
fective prevention such as needle-syringe programs (NSP) or
opioid substitution treatment (OST). Those that report that
they are providing injecting equipment are doing so at a
distribution rate of 2 needle-syringes per month, well below
the annual minimum threshold of 100 that demarcates low
coverage from medium coverage [11]. Among 57 reporting
countries, only 39 % of PWID have had an HIV test in the
previous 12 months and among 56 reporting countries, only 3
countries reported condom use above 75 % [11]. A global call
to action [62] and the 2010 Vienna Declaration [63] empha-
size the critical importance of science rather than ideology
informing HIV prevention. For example, reducing unmet need
among PWID by 60 % for NSP, OST, and ART from 2010 to
2015, would reduce HIV prevalence by 41%, 43%, and 30%
in the cities of Odessa, Karachi, and Nairobi, respectively
[64•]. With 30 % of new HIV infections outside sub-Saharan
Africa attributed to injecting, pragmatic harm reduction ap-
proaches, including experimentation with decriminalization of
personal drug use, as Portugal has done [65], are needed to
slow this expanding epidemic.
Young women constitute a key population in sub-Saharan
Africa, with those aged 15–24 years as much as 8 times more
likely than young men to be HIV-positive [66]. Although HIV
prevalence in young people aged 15 to 24 years fell more than
35 % between 2001 and 2011 [12], young women, particular-
ly in southern Africa, are still experiencing exceptionally high
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levels of HIV infection. To achieve greater impact on
preventing HIV transmission, an aggressive movement for
social transformation is required to address both the immedi-
ate practices that lead to HIVacquisition as well as the human
rights violations, harmful social norms, weak community and
leadership capacities, and disparities that underpin HIV risk
for women and for men in southern Africa [67]. The first step
is mobilization of communities for HIV prevention, with
strong male involvement, to design relevant strategies and
messages about the causes, consequences of, and solutions
to young women and girls’ vulnerability, including ‘zero
tolerance’ for gender-based violence and exploitation.
Conclusions
As global HIV prevalence stabilizes with increasing ART
scale-up and declining HIV incidence in many countries, there
is increasing interest in determining the mix of programs and
strategies that will be most cost-effective in reducing HIV
incidence most quickly in given epidemic settings. In addition
to correcting mismatches in resource allocation for HIV pre-
vention, the concept of tracking community viral load (CVL)
as a population-level biomarker for HIV burden and potential
transmission is compelling [68]. CVL is defined as the mean
of the most recent viral load test of all people living with HIV
within a specified geographic area over a specified period.
Ecological studies have demonstrated correlations between
decreases in CVL and reductions in HIV incidence. For ex-
ample, viral load reductions among PWID in Vancouver were
associated with decreased incidence in an HIV-negative
PWID cohort [69]. Increased uptake of more effective, potent,
and tolerable ART regimens in San Francisco between 2005
and 2008, concomitant with legal changes to facilitate HIV
testing, policy initiatives to promote expanded HIV testing,
increased acute HIV detection, and partner services, coincided
with a significant increase in the population rate of virologic
suppression from 46.8 % in 2005 to 78.1 % in 2008. Estimated
HIV incidence declined by over one-third between 2006 and
2008 [70••]. New empirical evidence from rural KwaZulu-
Natal, South Africa has resoundingly shown that individual
HIVacquisition risk significantly declines with increasing com-
munity ART coverage [71••]. Finally, CVL could be used to
predict the efficacy of early ART for prevention programs [72].
Future trends in the global HIV epidemic will be deter-
mined by the actions of individuals, couples, and communities
but, ultimately, it will be policy makers, implementers, civil
society, and funders that will be held accountable for choos-
ing, implementing, and evaluating tailored prevention pack-
ages judged to be optimal in specific circumstances [73], at the
same time that they scale up ART with its proven prevention
benefits and tangible impact on life expectancy [74]. As the
population of people living with HIV continues to age,
increasingly attention will need to turn to the challenges of
HIV and aging [75]. The potential for accelerated declines in
HIV incidence before the advent of an efficacious HIV vac-
cine is real. The glass is half full and the time to act is now.
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